Etiological drug treatment of human infection by Trypanosoma cruzi
Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.
Main Authors: | , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto de Medicina Tropical de São Paulo
1996
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0036-46651996000100007 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0036-466519960001000072006-09-22Etiological drug treatment of human infection by Trypanosoma cruziLevi,Guido CarlosLobo,Isa Maria FragaKallás,Esper GeorgesAmato Neto,Vicente Chronic Chagas' disease Antiparasitic treatment Benznidazole Nifurtimox Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.info:eu-repo/semantics/openAccessInstituto de Medicina Tropical de São PauloRevista do Instituto de Medicina Tropical de São Paulo v.38 n.1 19961996-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007en10.1590/S0036-46651996000100007 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Levi,Guido Carlos Lobo,Isa Maria Fraga Kallás,Esper Georges Amato Neto,Vicente |
spellingShingle |
Levi,Guido Carlos Lobo,Isa Maria Fraga Kallás,Esper Georges Amato Neto,Vicente Etiological drug treatment of human infection by Trypanosoma cruzi |
author_facet |
Levi,Guido Carlos Lobo,Isa Maria Fraga Kallás,Esper Georges Amato Neto,Vicente |
author_sort |
Levi,Guido Carlos |
title |
Etiological drug treatment of human infection by Trypanosoma cruzi |
title_short |
Etiological drug treatment of human infection by Trypanosoma cruzi |
title_full |
Etiological drug treatment of human infection by Trypanosoma cruzi |
title_fullStr |
Etiological drug treatment of human infection by Trypanosoma cruzi |
title_full_unstemmed |
Etiological drug treatment of human infection by Trypanosoma cruzi |
title_sort |
etiological drug treatment of human infection by trypanosoma cruzi |
description |
Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable. |
publisher |
Instituto de Medicina Tropical de São Paulo |
publishDate |
1996 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007 |
work_keys_str_mv |
AT leviguidocarlos etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi AT loboisamariafraga etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi AT kallasespergeorges etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi AT amatonetovicente etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi |
_version_ |
1756379664270491648 |